Public Health Paramount: Delhi High Court Upholds FSSAI’s Ban on Misleading ‘ORS’ Labelled Drinks

The Delhi High Court recently upheld the Food Safety and Standards Authority of India (FSSAI)’s decisive action prohibiting the manufacture and sale of beverages labeled as “ORS” (Oral Rehydration Solution) unless they strictly comply with the World Health Organization’s (WHO) medically prescribed formulation. This judgment underscores the primacy of public health over commercial interests and addresses a growing concern over misleading beverage products that falsely claim therapeutic benefits for dehydration treatment.​

Misuse of “ORS” Labeling and Public Health Risks

Oral Rehydration Solution, recognized globally as a life-saving medical formulation, is a balanced mixture of glucose, sodium chloride, and potassium chloride that plays a critical role in treating dehydration caused by diarrhoea. The WHO-recommended ORS formula works by enhancing the absorption of fluids and electrolytes in the body, preventing potentially fatal dehydration, particularly in vulnerable populations such as young children.​

However, over recent years, certain companies have marketed flavored beverages with excessive sugar content and inappropriate electrolyte ratios under the “ORS” label or as part of their trademark names without adhering to the standardized ORS composition. This misleading practice has perplexed consumers, especially parents, into purchasing these substitutes during diarrhoeal illness, inadvertently worsening dehydration instead of alleviating it. The excess sugar in such drinks can draw water into the intestines rather than the bloodstream, exacerbating fluid loss and potentially resulting in severe health consequences.

Expert Perspectives

Dr. Sivaranjini Santhosh, a paediatrician from Hyderabad whose sustained eight-year advocacy drive prompted this regulatory crackdown, emphasized the danger these pseudo-ORS drinks pose: “Some of these products had up to eight to ten times more sugar than what is safe. Instead of rehydrating, they actually worsen diarrhoea. Children end up in hospitals or worse.” She further highlighted the misleading packaging practices, noting that micro-sized disclaimers on such products fail to adequately warn consumers, many of whom may have limited literacy or health education.​

From a regulatory viewpoint, Additional Solicitor General Chetan Sharma stressed to the court that stringent prohibition is crucial to protect consumers from these deceptive products and to maintain truthful labeling standards imperative for public safety.​

Judicial Ruling and Regulatory Context

During litigation initiated by Dr. Reddy’s Laboratories challenging the FSSAI ban, the Delhi High Court affirmed the authority of FSSAI to enforce this prohibition. The court observed that public health considerations must take precedence over commercial interests and expressed serious concerns regarding the health hazards posed by counterfeit or misleading ORS-labelled beverages.​

The FSSAI’s October 2025 directive clarified that the “ORS” label must only be used for products meeting WHO standards and banned its use in trademarks or product names unless the product composition strictly aligns with medically approved formulations. This action builds upon prior measures from April 2022 aimed at curbing misleading advertisements and labeling of ORS substitutes, which had allowed some products with disclaimers but ultimately fell short in protecting consumers effectively.​

Public Health Implications

Diarrhoea remains a leading cause of mortality among children under five in India, accounting for a significant percentage of childhood deaths. The WHO-endorsed ORS has been heralded as one of the greatest public health achievements of the 20th century for preventing fatal dehydration. Therefore, ensuring public access to genuine ORS and preventing the distribution of misleading substitutes is vital.​

By reinforcing strict labeling regulations, this ruling aims to enhance consumer protection and decrease morbidity caused by improper treatment of dehydration. For healthcare professionals, caregivers, and parents alike, the decision serves as a critical reminder to carefully verify that the ORS products used conform to scientifically validated standards rather than rely solely on product names or packaging claims.​

Limitations and Ongoing Challenges

While the court ruling is an important victory for consumer safety, enforcement challenges persist. Some manufacturers possess unsold stocks of banned products, and logistical issues surrounding relabeling and recall remain complex. The court has directed affected companies to submit formal representations regarding existing stock while maintaining the ban until compliance is ensured.​

Additionally, public education on the importance of using authentic ORS and understanding proper dehydration management is essential to complement regulatory measures, especially in rural or low-literacy settings where misinterpretation of labels is more common.​

Conclusion

The Delhi High Court’s endorsement of FSSAI’s regulatory action exemplifies a robust commitment to public health safety, particularly safeguarding vulnerable populations from deceptive marketing practices that can exacerbate serious medical conditions. This legal precedent reinforces the necessity of evidence-based product standards and truthful labeling in healthcare-related consumer products.

For consumers and healthcare providers, the message is clear: rely on scientifically validated ORS formulations for dehydration treatment, remain vigilant against misleading labels, and advocate for regulatory vigilance to uphold public safety.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References: